Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Michael J. Morris,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H. Park,Tomasz M. Beer,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard Adam Messmann,Bernd J. Krause,A. Oliver Sartor

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

2021

Michael J. Morris
Johann S. de Bono
Kim N. Chi
Karim Fizazi
Ken Herrmann
Kambiz Rahbar
Scott T. Tagawa
Luke T. Nordquist
Nitin Vaishampayan
Ghassan El-Haddad
Chandler H. Park
Tomasz M. Beer
Wendy J Pérez-Contreras
Michelle DeSilvio
Euloge Kpamegan
Germo Gericke
Richard Adam Messmann
Bernd J. Krause
A. Oliver Sartor

LBA4Background: Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) is highly expressed ...

Keywords:

in patient
Cancer research
membrane antigen
Medicine
castration resistant
Prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations